Program
#4 Cancer: Metastasis GROUP: 0.13, 0.46, 0.83, 12.69, 93.5, 221.5, 434.71, 512.33, 667, 753.07
In 2017, ETDFL introduced Program #4, the Metastasis Cancer Frequency Group, specifically developed to target and treat metastatic cancers. These are cancers that have spread from their original location to other parts of the body, posing significant challenges for treatment and requiring precise and targeted therapy. The frequencies in this group, including 0.13 kHz, 0.46 kHz, 0.83 kHz, 12.69 kHz, 93.5 kHz, 221.5 kHz, 434.71 kHz, 512.33 kHz, 667 kHz, and 753.07 kHz, were meticulously selected based on data sourced from ETDFL Data, a collection of client health records gathered through the Quantum SCIO Bioresonance Machine. This technology enabled the identification of the most effective frequencies for addressing metastasized cancer, ensuring that each frequency could resonate with specific types of cancer spread throughout the body.
The Metastasis Cancer Group was designed to treat a wide variety of metastatic cancers, from Adrenocortical Cancer Metastasis and Lung Cancer Metastasis to more complex conditions like Pancreatic Cancer Metastasis and Brain Tumor Metastasis. The frequencies in this program were particularly effective in helping to address the spread of cancerous cells by targeting specific metastases in different organs, such as the liver, bones, lungs, and lymph nodes. By using these frequencies, the BeamRay system offered a more tailored approach to managing the complexities of metastatic disease.
As with other BeamRay programs, the frequencies were transmitted through light via the white light mat and infrared mat, both of which were essential components of the treatment system. The mats, once wrapped around the affected area of the body, emitted light waves that carried the therapeutic frequencies. The infrared mat was particularly useful for treating deeper tissues, delivering frequencies that penetrated the body’s surface to reach internal organs or deep-seated metastases. Meanwhile, the white light mat offered a broader exposure, providing a more general treatment for areas closer to the skin’s surface.
The BeamRay controller allowed patients to select their preferred treatment time from 30 minutes, 60 minutes, 90 minutes, or 120 minutes, allowing flexibility depending on individual needs. This timing feature ensured consistent therapy while enabling patients to adjust the duration based on their comfort and treatment goals. During a typical treatment session, patients would place the mats over or around the area where metastasis was suspected or identified. The light from the mats would then radiate the selected frequencies into the body, interacting with cancerous cells and promoting the body’s natural healing process. This non-invasive, targeted treatment was designed to complement other cancer therapies, offering patients an alternative or adjunctive approach to dealing with metastatic disease.
For over eight years, the Metastasis Cancer Frequency Group was used by patients around the world, with many reporting significant improvements in their ability to manage metastasis. The frequencies in Program #4 were employed as an alternative or supplementary treatment, aligning with Dr. Rife's original vision of using electromagnetic frequencies to influence the body’s cellular environment. These frequencies were fine-tuned to help slow the spread of cancer and enhance the body’s natural defenses against the growth of metastatic tumors.
The Metastasis Cancer Treatment Frequency Group was developed by the ETDFL Data Group, leveraging data from 12 specialized clinics worldwide that utilized the Quantum SCIO Bioresonance Machine to record actual disease frequencies from clients. This technology enabled clinicians to identify the most effective frequencies for treating metastatic cancers, ensuring that each frequency was tailored to address the complexities of the disease. These findings were then incorporated into the BeamRay system, offering a scientific, data-driven solution to patients struggling with metastatic cancer.
The success of this program highlighted the potential of frequency-based therapy in cancer treatment. By utilizing these targeted frequencies, patients were able to experience a level of treatment that was both non-invasive and highly specific to their needs, a stark contrast to the more generalized approach of traditional therapies. As a result, the Metastasis Cancer Frequency Group became an invaluable part of the BeamRay suite of treatment options, offering hope and healing to many patients facing the daunting challenge of metastatic cancer.
The continued use and success of Program #4 underscored the power of frequency medicine and its potential to transform the way metastatic cancers are managed. With each session, the BeamRay system demonstrated its ability to assist the body in fighting cancer through the power of light and resonance, a fitting continuation of Dr. Rife’s groundbreaking work and a testament to the power of modern technological advancements in healing.
Program 3 is an alternate set that can be used for the treatment of
Adrenocortical Cancer Metastasis, Bladder Cancer Metastasis, Bone Cancer Metastasis, Brain Tumor Cancer Metastasis, Brain Stem Glioma Cancer Metastasis, Cerebellar Astrocytoma Cancer Metastasis, Cerebral Astrocytoma Cancer Metastasis, Ependymoma Cancer Metastasis, Medulloblastoma Cancer Metastasis, S.P.N. & Pineal Tumors Cancer Metastasis, Visual Pathway and Hypothalamic Glioma Cancer Metastasis, Breast Cancer Metastasis, Cervical / Uterus Cancer Metastasis, Colon Cancer Metastasis, Digestive System Cancer Metastasis, Endocrine Gland Cancer Metastasis, Endometrium Cancer Metastasis, Esophageal Cancer Metastasis, Ewings PNET Primitive Neuroectodermal Tumor Cancer Metastasis, Extracranial Germ Cell Tumor Cancer Metastasis, Extrahepatic Bile Duct Cancer Metastasis, Eye Cancer Metastasis, Gallbladder Cancer Metastasis, Gastric Stomach Cancer Metastasis, Gastrointestinal Cancer Metastasis, Genital Female Cancer Metastasis, Genital Male Cancer Metastasis, Germ Cell Cancer Metastasis, Gestational Tumor Cancer Metastasis, Head and Neck Cancer Metastasis, Hypopharyngeal Cancer Metastasis, Intestinal Gastrointestinal Cancer Metastasis, Islet Cell Carcinoma Cancer Metastasis, Kidney Renal Cancer Metastasis, Larynx Cancer Metastasis, Leukemia Cancer Metastasis, Leukemia Acute Myeloid Cancer Metastasis, Leukemia Chronic Lymph Cancer Metastasis, Leukemia Hairy Cell Cancer Metastasis, Leukemia Lymphoblastic Cancer Metastasis, Leukemia Myelogenous Cancer Metastasis, Lip and Oral Cavity Cancer Metastasis, Liver Cancer Metastasis, Lung Non-Small Cell Cancer Metastasis, Lung Small Cell Cancer Metastasis, Lymphoma Cancer Metastasis, Lymphoma B-Cell Cancer Metastasis, Lymphoma Malignant Cancer Metastasis, Lymphoma Non-Hodgkin Cancer Metastasis, Lymphoma T-Cell Cancer Metastasis, Lymphoplasmacytic Cancer Metastasis, Malignant Mesothelioma Cancer Metastasis, Melanoma Cancer Metastasis, Merkel Cell Cancer Metastasis, Metastasis Squamous Cancer, Mouth Cancer Metastasis, Multiple Myeloma inc Plasma C Cancer Metastasis, Mycosis Fungoides Cancer Metastasis, Myelodysplastic Syndrome Cancer Metastasis, Myeloproliferative Disorders Cancer Metastasis, Nasopharyngeal Cancer Metastasis, Nervous System Neoplasms Cancer Metastasis, Neuroblastoma Cancer Metastasis, Oral Cancer Metastasis, Oropharyngeal Cancer Metastasis, Otorhinolaryngologic Cancer Metastasis, Ovarian Cancer Metastasis, Ovarian Epithelial Cancer Metastasis, Ovarian Germ Cell Cancer Metastasis, Ovarian Low Malignant Potential Tumor Cancer Metastasis, Pancreatic, Exocrine & Islet Cell Cancer Metastasis, Paranasal Sinus and Nasal Cavity Cancer Metastasis, Parathyroid Cancer Metastasis, Penile [Penis] Cancer Metastasis, Pheochromocytoma [Non-Benign] Cancer Metastasis, Pituitary Cancer Metastasis, Plasma Cell Neoplasm Cancer Metastasis, Prostate Cancer Metastasis, Rectal [Rectum] Cancer Metastasis, Renal Cell [Kidney] Cancer Metastasis, Respiratory Tract Cancer Metastasis, Rhabdomyosarcoma Cancer Metastasis, Salivary Gland Cancer Metastasis, Sarcoma General Cancer Metastasis, Sezary Syndrome Cancer Metastasis, Skin Cancer Metastasis, Skin Kaposi’s Sarcoma Cancer Metastasis, Skin Melanoma Cancer Metastasis, Skin T-Cell Lymph Cancer Metastasis, Small Intestine Cancer Metastasis, Soft Tissue Sarcoma Cancer Metastasis, Squamous Cell Carcinoma Cancer Metastasis, Stomach Cancer Metastasis, Testicular [Testis] Cancer Metastasis, Thoracic Cancer Metastasis, Thyroid Cancer Metastasis, Tonsil Cancer Metastasis, Urethral [Urinary] Cancer Metastasis, Urinary Bladder Cancer Metastasis, Urologic Neoplasms Cancer Metastasis, Uterine Sarcoma Cancer Metastasis, Uterine Cervical Cancer Metastasis, Vaginal Cancer Metastasis, Vulvar Cancer Metastasis, Wilms Tumor Cancer Metastasis.
BeamRay Infrared Therapy Device
Supporting Recovery and Pain Relief with Advanced Infrared Technology for Cancer Care
5 Treatment Modes
● BeamRay™ Original
● Cancer Comprehensive
● Cancer Comp (Alternative Set)
● Cancer Metastasis
● Dr Rife’s Specialized MOR CW
Automatic Timer
Automatic timer permits 30,60,90 and 120 minutes
Comes with Adjustable Strap
The BeamRay device features an adjustable velcro strap, offering a universal fit that ensures the device stays comfortably and securely in place on any targeted area for all users.
BeamRay Therapy Device
Advanced BeamRay Technology for Cancer Care
Multiple BeamRay Light Mats
● BeamRay White Light Mat
● BeamRay Infrared Light Mat
Adjustable Intensity
Adjustable Intensity
Switch from low intensity to High intensity with the press of a button
140 Programmable Infrared LEDs
Each of the 140 LEDs on the BeamRay Mats operate on specialized frequency programs tailored to target specific Cancer sites, enhancing the effectiveness of treatment.
This powerful, BeamRay device is designed with 2 mat options. One mat features an array of Visible Infrared RED LED lights, with each mat containing 140 LEDs optimized for targeting cancers. The 2nd mat is a 140 LED White light mat with an array of White LEDs simulating the original Dr Rife BeamRay. Together, the LED lights work to target various cancer types and assist in treatment and recovery.
